Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling

Gut

Volumn 62, Issue 4, 2013, Pages 550-560

  De Boeck, Astrid ^a   Pauwels, Patrick ^b   Hensen, Karen ^c   Rummens, Jean Luc ^c   Westbroek, Wendy ^d   Hendrix, An ^a   Maynard, Dawn ^d   Denys, Hannelore ^a   Lambein, Kathleen ^a   Braems, Geert ^a   Gespach, Christian ^e   Bracke, Marc ^a   De Wever, Olivier ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c Laboratory of Experimental Hematology   (Belgium)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^e CENTRE DE RECHERCHE SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; COLLAGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; LAPATINIB; NEU DIFFERENTIATION FACTOR; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CARCINOGENESIS; CELL ASSAY; CELL COUNT; CELL CYCLE; CELL INTERACTION; CELL INVASION; CELL MEMBRANE; CELL SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER METASTASIS; MASS SPECTROMETRY; MESENCHYMAL STEM CELL; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN LOCALIZATION; PROTEIN SECRETION; RECEPTOR UPREGULATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANALYSIS OF VARIANCE; BLOTTING, WESTERN; CELL COUNT; CELL LINE, TUMOR; CELL MOVEMENT; CHI-SQUARE DISTRIBUTION; CHROMATOGRAPHY, LIQUID; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MASS SPECTROMETRY; MESENCHYMAL STROMAL CELLS; NEUREGULIN-1; PARACRINE COMMUNICATION; PHOSPHORYLATION; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC;

EID: 84874666281     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-301393     Document Type: Article

References (57)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36.
2. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003;200:429-47. (Pubitemid 36818244)
3. Quante M, Tu SP, Tomita H, et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011;19:257-72.
4. Shinagawa K, Kitadai Y, Tanaka M, et al. Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer 2010;127:2323-33.
5. Tsai KS, Yang SH, Lei YP, et al. Mesenchymal stem cells promote formation of colorectal tumors in mice. Gastroenterology 2011;141:1046-56.
6. De Wever O, Demetter P, Mareel M, et al. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 2008;123:2229-38.
7. Stappenbeck TS, Miyoshi H. The role of stromal stem cells in tissue regeneration and wound repair. Science 2009;324:1666-9.
8. Sergina NV, Moasser MM. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med 2007;13:527-34. (Pubitemid 350130347)
9. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16. (Pubitemid 44036456)
10. Graus-Porta D, Beerli RR, Daly JM, et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-55. (Pubitemid 27151960)
11. Shi F, Telesco SE, Liu Y, et al. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci U S A 2010;107:7692-7.
12. Jones RB, Gordus A, Krall JA, et al. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 2006;439:168-74. (Pubitemid 43083134)
13. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37. (Pubitemid 33674041)
14. Begnami MD, Fukuda E, Fregnani JH, et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. J Clin Oncol 2011;29:3030-6.
15. Grivas PD, Antonacopoulou A, Tzelepi V, et al. HER-3 in colorectal tumourigenesis: from mRNA levels through protein status to clinicopathologic relationships. Eur J Cancer 2007;43:2602-11. (Pubitemid 350103546)
16. Beji A, Horst D, Engel J, et al. Towards the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer. Clin Cancer Res 2012;18:956-68.
17. Carraway KL 3rd, Weber JL, Unger MJ, et al. Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. Nature 1997;387:512-16. (Pubitemid 27235470)
18. Crovello CS, Lai C, Cantley LC, et al. Differential signaling by the epidermal growth factor-like growth factors neuregulin-1 and neuregulin-2. J Biol Chem 1998;273:26954-61. (Pubitemid 28471717)
19. Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 2008;9:437-52. (Pubitemid 351704944)
20. Montero JC, Yuste L, Diaz-Rodriguez E, et al. Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme. Mol Cell Neurosci 2000;16:631-48. (Pubitemid 32001311)
21. Koninckx R, Hensen K, Daniels A, et al. Human bone marrow stem cells co-cultured with neonatal rat cardiomyocytes display limited cardiomyogenic plasticity. Cytotherapy 2009;11:778-92.
22. Vermeulen SJ, Bruyneel EA, Bracke ME, et al. Transition from the noninvasive to the invasive phenotype and loss of alpha-catenin in human colon cancer cells. Cancer Res 1995;55:4722-8.
23. De Wever O, Nguyen QD, Van Hoorde L, et al. Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J 2004;18:1016-18. (Pubitemid 39561510)
24. Celis JE, Gromov P, Cabezón T, et al. Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment. Mol Cell Proteomics 2004;3:327-44. (Pubitemid 38702087)
25. Hendrix A, Maynard D, Pauwels P, et al. Effect of the secretory small GTPase Rab27B on breast cancer growth, invasion, and metastasis. J Natl Cancer Inst 2010;102:866-80.
26. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41. (Pubitemid 27456390)
27. Oltval ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death. Cell 1993;74:609-19. (Pubitemid 23259742)
28. Badache A, Hynes NE. A new therapeutic antibody masks ErbB2 to its partners. Cancer Cell 2004;5:299-301.
29. Xia W, Liu LH, Ho P, et al. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR//ErbB2 kinase inhibitor GW572016. Oncogene 2004;23:646-53. (Pubitemid 38241266)
30. Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc) 2005;41:107-27. (Pubitemid 40461533)
31. Meyer D, Yamaai T, Garratt A, et al. Isoform-specific expression and function of neuregulin. Development 1997;124:3575-86. (Pubitemid 27470041)
32. Stove C, Stove V, Derycke L, et al. The heregulin/human epidermal growth factor receptor as a new growth factor system in melanoma with multiple ways of deregulation. J Invest Dermatol 2003;121:802-12. (Pubitemid 37239125)
33. Lu HS, Hara S, Wong LW, et al. Post-translational processing of membrane-associated neu differentiation factor proisoforms expressed in mammalian cells. J Biol Chem 1995;270:4775-83.
34. Zischek C, Niess H, Ischenko I, et al. Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. Ann Surg 2009;250:747-53.
35. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557-63. (Pubitemid 47525152)
36. De Boeck A, Narine K, De Neve W, et al. Resident and bone marrow-derived mesenchymal stem cells in head and neck squamous cell carcinoma. Oral Oncol 2010;46:336-42.
37. Holmes WE, Sliwkowski MX, Akita RW, et al. Identification of heregulin, a specific activator of p185erbB2. Science 1992;256:1205-10.
38. Venkateswarlu S, Dawson DM, St Clair P, et al. Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells. Oncogene 2002;21:78-86. (Pubitemid 34076380)
39. Sheng Q, Liu X, Fleming E, et al. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 2010;17:298-310.
40. Wilson TR, Lee DY, Berry L, et al. Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell 2011;20:158-72.
41. Noguchi H, Sakamoto C, Wada K, et al. Expression of heregulin alpha, erbB2, and erbB3 and their influences on proliferation of gastric epithelial cells. Gastroenterology 1999;117:1119-27. (Pubitemid 29512671)
42. Liles JS, Arnoletti JP, Kossenkov AV, et al. Targeting ErbB3-mediated stromalepithelial interactions in pancreatic ductal adenocarcinoma. Br J Cancer 2011;105:523-33.
43. Wislet-Gendebien S, Hans G, Leprince P, et al. Plasticity of cultured mesenchymal stem cells: switch from nestin-positive to excitable neuron-like phenotype. Stem Cells 2005;23:392-402. (Pubitemid 40404458)
44. Achyut BR, Yang L. Transforming growth factor-b in the gastrointestinal and hepatic tumor microenvironment. Gastroenterology 2011;141:1167-78.
45. Kitamura T, Kometani K, Hashida H, et al. SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. Nat Genet 2007;39:467-75. (Pubitemid 46514777)
46. Adam L, Vadlamudi R, Kondapaka SB, et al. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 1998;273:28238-46. (Pubitemid 28496122)
47. Plowman GD, Green JM, Culouscou JM, et al. Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature 1993;366:473-5. (Pubitemid 24013882)
48. Carraway KL 3rd, Sliwkowski MX, Akita R, et al. The erbB3 gene product is a receptor for heregulin. J Biol Chem 1994;269:14303-6. (Pubitemid 24191194)
49. Yonezawa M, Wada K, Tatsuguchi A, et al. Heregulin-induced VEGF expression via the ErbB3 signaling pathway in colon cancer. Digestion 2009;80:215-25.
50. Yoshioka T, Nishikawa Y, Ito R, et al. Significance of integrin alphavbeta5 and erbB3 in enhanced cell migration and liver metastasis of colon carcinomas stimulated by hepatocyte-derived heregulin. Cancer Sci 2010;101:2011-18.
51. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005;438:820-7. (Pubitemid 41753060)
52. Oskarsson T, Acharyya S, Zhang XH, et al. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med 2011;17:867-74.
53. Yonesaka K, Zejnullahu K, Okamoto I, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011;3:99ra86.
54. Ng K; Dana-Farber Cancer Institute study. Pertuzumab and cetuximab in treating patients with locally advanced or metastatic colorectal cancer that did not respond to previous cetuximab. 2007. http://clinicaltrials.gov/ct2/show/ NCT00551421
55. U3 Pharma GmbH. Phase I study of U3P1287/01, including patients with advanced solid tumors. 2008. http://clinicaltrials.gov/ct2/show/NCT00730470
56. Schoeberl B, Faber AC, Li D, et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010;70:2485-94.
57. Merrimack Pharmaceuticals. Phase I safety study of the drug MM-121 in patients with advanced solid tumors resisting ordinary treatment. 2008. http://clinicaltrials.gov/ct2/show/NCT00734305PAGEfractiontrail=10.75